TAO SYNERGIES INC

TAOXNASDAQ

🏆 #4021 by market capEarnings Aug 12US Equity

$3.55▼ $0.07 (−1.93%)

Live

1h—

24h▼ 1.9%

7d▲ 2.3%

14d▲ 7.9%

30d▼ 1.7%

1y▼ 56.8%

🏦Market Cap

$27M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

37.9x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $3.51 – $3.57
52-Week Range: $3.18 – $10.00
Volume: $3.36B
Avg Volume: $4.44B
Shares Outstanding: 7.5M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $299,061
Last Q Revenue: $388,774
P/E Ratio: —
P/S Ratio: 37.9x
EPS (TTM): $-13.32
Dividend Yield: 1.24%

Why Investors Own TAOX

✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$299,061▲ +32.5% YoY

Gross Margin (TTM)

34.2%▲ +0.5% YoY

Operating Income (TTM)

$51,738▲ +32.5% YoY

Free Cash Flow (TTM)

$41,869▲ +32.5% YoY

About TAO SYNERGIES INC

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

🦦